Carregant...
Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines
BACKGROUND: More than 50% of metastatic melanoma patients have a specific mutation in the serine/threonine kinase BRAF. This results in constitutive activation of the RAS-RAF-MEK-ERK-MAP kinase pathway, which causes uncontrolled cell growth. Vemurafenib (PLX4032) is an oral chemotherapeutic agent th...
Guardat en:
| Publicat a: | BMC Cancer |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6014033/ https://ncbi.nlm.nih.gov/pubmed/29929490 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4583-3 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|